American Society of Clinical Oncology 2018 Annual Meeting


From June 1-5, the American Society of Clinical Oncology (ASCO) will host its annual meeting in Chicago, Illinois. The conference brings together oncologists from all over the world to present groundbreaking research and scientific advances in cancer care. The focus of this year's meeting is expanding the reach of precision medicine. Journal of Clinical Pathways staff will be on the ground to provide comprehensive coverage of the ASCO Annual Meeting, which will be featured in our June 2018 issue. Be sure to check back next month to read detailed reports of the research presented!


Katherine Reeder-Hayes, MD, MBA, MSc, described the potential role of real-world evidence as a compliment to clinical trials as well as successful implementation of Big Data for real-world evidence generation.

Read More







On Saturday afternoon, the ASCO town hall convened to share different perspectives on administrative burden, pharmacy benefit managers, and clinical pathways.




In a session Saturday morning, Artia Hurria, MD, FASCO, detailed the current state of treatment for older patients with cancer and the reasons why further efforts are needed to improve the evidence base in this population.








James Lin Chen, MD, discussed the various challenges and considerations of enabling precision medicine with health information technology.





A new study sought to better define real-world initiation, management, and outcomes of patients with chronic lymphocytic leukemia treated with a standard-of-care therapy.






The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer.





Significant Economic Burden Associated With Early Progression in Newly-Diagnosed Myeloma

A new study attempted to quantify the economic burden of early progression in patients with newly-diagnosed multiple myeloma.

Read More






Improvements in life expectancy and quality-adjusted life years as a result of chimeric antigen receptor T-cell therapy is dependent upon immediate access to treatment.






A new study examined post-treatment evaluation methods of head and neck squamous cell carcinoma in the context of advanced imaging and value-based care.




A recent study sought to determine the factors associated with durable remission after a complete response to CD19-targeting CAR-T therapy in adult patients with B-cell ALL.



A systematic review of value-based health care delivery models in oncology care found that reports of outcomes are often lacking and show varying degrees of quality improvement.



A new real-world study compared the health care resource utilization and costs between patients treated for multiple myeloma with and without renal impairment.



An economic model comparing different types of genetic testing in metastatic non-small cell lung cancer showed that next-generation sequencing is more cost-effective than testing for one or a limited number of genes at a given time.